All In Biotech

Drug Trial Radar · NCT01359982

Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects

A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of RRx-001 in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Curative Therapies

Last checked: Nov 19, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

26

Actual

Start

Sep 2011

Primary completion

Feb 2015

Study completion Feb 2015

Sponsor

Lead sponsor
EpicentRx, Inc.Industry
Sponsor type
Industry
First posted
May 25, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001 for injection in subjects with advanced solid tumors or lymphomas for which there are no currently accepted curative therapies. This study will also conduct an exploratory evaluation of objective tumor response using CT or MRI.

Conditions

  • Malignant Solid Tumor
  • Lymphomas

Interventions

  • RRx-001Drug

    Dose level 1 (10 mg/m2)

  • RRx-001Drug

    Dose Level 2 (16.7 mg/m2)

  • RRx-001Drug

    Dose Level 3 (24.6 mg/m2)

  • RRx-001Drug

    Dose Level 4 (33 mg/m2)

  • RRx-001Drug

    Dose Level 5 (55.0 mg/m2)

  • RRx-001Drug

    Dose Level 6 (83 mg/m2)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients Who Had an Adverse EventsTime frame: From time of receiving a dose of RRx-001 through 92 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Moores University of California San Diego Cancer Center

    La Jolla, California

  • Sarah Cannon Research Institute

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.